Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor ...

Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results

Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete ...
Medical Dialogues

Icotrokinra Shows Strong Efficacy and Safety in Plaque Psoriasis: Meta-Analysis

Libya: New research, published in the International Journal of Dermatology, has demonstrated high efficacy and good ...
Physician's Weekly

Q&A: Real-World Data on Tildrakizumab for Plaque Psoriasis

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.
Fierce Pharma

'SNL' pokes fun at mysteries of Amgen's Otezla for plaque psoriasis

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...